SCHEMBL1507705

SCHEMBL1507705

CC(c1ccccc1)(c1ccc(OC(=O)CCl)cc1)c1ccc(OC(=O)CCl)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.47
MAPT P10636 2/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
ESR1 P03372 2/20 0.46
ESR2 Q92731 2/20 0.46
ELANE P08246 2/20 0.44
KMT2A Q03164 6/20 0.43
MEN1 O00255 4/20 0.43
RAB9A P51151 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
KDM4E B2RXH2 7/20 0.43
ALDH1A1 P00352 6/20 0.43
HTT P42858 2/20 0.43
POLB P06746 2/20 0.40
LMNA P02545 3/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
BCHE P06276 1/20 0.40
CHRM2 P08172 1/20 0.40
CYP2C19 P33261 1/20 0.40
HIF1A Q16665 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14039459 0.94 ELANE (0.47) TDP1MAPTL3MBTL1ESR1ESR2
SCHEMBL1507858 0.93 MAPT (0.44) TDP1MAPTL3MBTL1ESR1ELANE
SCHEMBL14039420 0.87 MAPT (0.46) TDP1MAPTL3MBTL1ELANEKMT2A
SCHEMBL13290630 0.83 MAPT (0.53) TDP1MAPTL3MBTL1KMT2AMEN1
SCHEMBL14039460 0.82 ELANE (0.47) MAPTL3MBTL1ESR1ELANEKMT2A
SCHEMBL10597574 0.81 MAPT (0.51) TDP1MAPTL3MBTL1ESR1ESR2
SCHEMBL137047 0.80 CYP19A1 (0.52) TDP1MAPTL3MBTL1ELANEKMT2A
SCHEMBL14039418 0.80 ELANE (0.59) TDP1MAPTL3MBTL1ESR1ESR2
SCHEMBL16394899 0.80 MAPT (0.53) TDP1MAPTL3MBTL1ESR1ESR2
SCHEMBL21942015 0.80 MAPT (0.53) TDP1MAPTL3MBTL1ESR1ESR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2305246-B1 Tumor necrosis factor inhibitors UNIV PENNSYLVANIA (US) 2015-08-26 EP disclosed
EP-2305246-B1 Tumor necrosis factor inhibitors UNIV PENNSYLVANIA (US) 2015-08-26 EP disclosed
US-9096607-B2 Tumor necrosis factor inhibitors THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2015-08-04 US disclosed
US-9096607-B2 Tumor necrosis factor inhibitors THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2015-08-04 US disclosed
US-20140256803-A1 TUMOR NECROSIS FACTOR INHIBITORS THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2014-09-11 US disclosed
US-20140256803-A1 TUMOR NECROSIS FACTOR INHIBITORS THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2014-09-11 US disclosed
US-8765810-B2 Tumor necrosis factor inhibitors THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2014-07-01 US disclosed
US-8765810-B2 Tumor necrosis factor inhibitors THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2014-07-01 US disclosed
EP-1845970-B1 TUMOR NECROSIS FACTOR INHIBITORS CEPHALON INC (US) 2013-08-28 EP disclosed
EP-1845970-B1 TUMOR NECROSIS FACTOR INHIBITORS CEPHALON INC (US) 2013-08-28 EP disclosed
US-20130072562-A1 TUMOR NECROSIS FACTOR INHIBITORS CEPHALON, INC. (US) 2013-03-21 US disclosed
US-8318699-B2 Tumor necrosis factor inhibitors THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2012-11-27 US disclosed
US-8318699-B2 Tumor necrosis factor inhibitors THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2012-11-27 US disclosed
US-8318699-B2 Tumor necrosis factor inhibitors THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2012-11-27 US disclosed
EP-2305246-A1 Tumor necrosis factor inhibitors Ception Therapeutics, Inc. (US) 2011-04-06 EP disclosed
EP-2305246-A1 Tumor necrosis factor inhibitors Ception Therapeutics, Inc. (US) 2011-04-06 EP disclosed
EP-2298295-A1 Tumor necrosis factor inhibitors Ception Therapeutics, Inc. (US) 2011-03-23 EP disclosed
US-20090221527-A1 TUMOR NECROSIS FACTOR INHIBITORS CEPTION THERAPEUTICS, INC. (US) 2009-09-03 US disclosed
US-20090221527-A1 TUMOR NECROSIS FACTOR INHIBITORS CEPTION THERAPEUTICS, INC. (US) 2009-09-03 US disclosed
US-20090221527-A1 TUMOR NECROSIS FACTOR INHIBITORS CEPTION THERAPEUTICS, INC. (US) 2009-09-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090221527-A1 TUMOR NECROSIS FACTOR INHIBITORS TNFRSF1A, TNF, TNFRSF9 TDP1 3407/4885MAPT 3981/4885L3MBTL1 4132/4885
US-20140256803-A1 TUMOR NECROSIS FACTOR INHIBITORS TNFRSF1A, TNF, TNFRSF9 TDP1 3407/4885MAPT 3981/4885L3MBTL1 4132/4885
US-20130072562-A1 TUMOR NECROSIS FACTOR INHIBITORS TNFRSF1A, TNF, TNFRSF9 TDP1 3407/4885MAPT 3981/4885L3MBTL1 4132/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.